Trial Profile
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2023
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Abiraterone acetate; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 13 Sep 2023 Planned End Date changed from 31 Aug 2023 to 31 Aug 2024.
- 02 Aug 2022 Planned End Date changed from 31 Aug 2021 to 31 Aug 2023.
- 01 Jun 2020 Planned End Date changed from 1 Dec 2019 to 31 Aug 2021.